Global Meglitinide Market Trends and Insights
Rising Type 2 Diabetes Burden
The increasing prevalence of type 2 diabetes continues to drive demand in the Meglitinides market, particularly in countries where affordability and treatment access are key priorities. The IDF estimated that 589 million adults aged 20 to 79 years were living with diabetes in 2025, representing 11.11% of the global adult population. This figure is projected to reach 853 million by 2050. Middle-income countries recorded the highest age-standardized diabetes prevalence at 11.46%, positioning China, India, and Brazil as key demand centers. The IDF also reported diabetes prevalence of 12.26% in urban areas and 9.23% in rural areas. This gap highlights the importance of peri-urban primary care centers in diabetes management and treatment delivery.Repaglinide remains competitive due to its affordability, oral administration, and established use among general practitioners. Low-cost generic products remain relevant where patient out-of-pocket spending or payer budget limitations restrict access to newer medicines. China’s 2025 National Reimbursement Drug List includes repaglinide, nateglinide, and mitiglinide calcium as Category B drugs. This reimbursement coverage supports access across public hospitals and community health centers. The Meglitinides market benefits when national reimbursement systems continue to support established oral treatment options, particularly in cost-sensitive healthcare systems.
Need for Postprandial Glucose Control
Meglitinides support patients who require glucose control aligned with meal timing. Their short-acting, glucose-dependent mechanism helps manage postprandial glucose excursions that may persist with longer-acting therapies. The American Diabetes Association recommends reassessing meglitinide doses when initiating a new glucose-lowering medicine to manage treatment burden and hypoglycemia risk.The drug class remains relevant for patients whose meal patterns or clinical requirements favor short-acting therapy. Meal-responsive treatment is particularly applicable in Japan, China, South Korea, and Germany, where physician familiarity and patient needs support continued use. In Japan, 41.6% of physicians surveyed in September 2025 identified mitiglinide as their most frequently prescribed rapid-acting insulin secretagogue. Mitiglinide ranked ahead of repaglinide at 35.5% and nateglinide at 22.9%. Its selective Kir6.2/SUR1 channel activity and lower within-class hypoglycemia incidence support its use in older patients and those with cardiovascular concerns. These clinical attributes enable the Meglitinides market to retain a focused role as treatment algorithms evolve.
Hypoglycemia Risk
Hypoglycemia remains a key clinical constraint on the broader adoption of meglitinides. The American Diabetes Association advises clinicians to reassess meglitinide dosages when adding another glucose-lowering medication. This guidance is particularly relevant in markets where clinicians closely follow updated treatment standards. Older patients require careful monitoring, as hypoglycemic events can lead to falls, hospitalization, and other complications.The need for meal-linked dosing also increases the treatment burden for patients with irregular eating patterns. However, this limitation does not result in the complete withdrawal of the drug class. Physicians may prefer mitiglinide because of its relatively lower within-class incidence of hypoglycemia. Concerns regarding weight gain and frequent meal-dependent dosing reduce the convenience of meglitinides in North America, Europe, and Australia. Therefore, the meglitinides market relies on appropriate patient selection and careful dose management rather than broad first-line adoption. The class continues to serve specific patient segments requiring short-acting glucose control.
Other drivers and restraints analyzed in the report include:
- Continued Use of Oral Antidiabetic Therapies
- Role in Combination Therapy
- Competition From Newer Antidiabetic Therapies
Segment Analysis
Repaglinide held 53.45% of the meglitinides market by molecule in 2025. Broad generic availability, national formulary inclusion, and an established clinical track record supported its leading position. Its availability as monotherapy and in fixed-dose combinations further strengthened adoption. The product supports meal-related insulin secretion with relatively rapid clearance.Nateglinide held a smaller market share but addressed demand from patients who benefit from a short half-life and lower interaction potential. As a phenylalanine derivative, it provides a rapid insulin response. Mitiglinide is projected to record the highest growth among molecules, at a CAGR of 3.45% through 2031. A September 2025 physician survey in Japan ranked mitiglinide first among rapid-acting insulin secretagogues, while China retained mitiglinide calcium on its 2025 reimbursement list.
Generic formulations held 65.78% of the meglitinides market by product status in 2025. Patent expirations and established bioequivalence pathways supported generic adoption across key molecules. Active pharmaceutical ingredient supply from India and China reinforced price competition. In the United States, Macleods Pharmaceuticals, Aurobindo Pharma, Chartwell RX LLC, and Rising Pharma Holdings supply repaglinide products, while CMS pricing data showed a price of USD 0.09 per tablet in July 2026.
Originator products are forecast to grow at a CAGR of 4.67% through 2031, driven by sustained demand in selected countries. Glufast retains brand recognition in Japan, while hospital tenders and physician familiarity support demand in Germany and Brazil. NovoNorm remains the originator reference product for repaglinide in the European Union. European pharmacovigilance and manufacturing requirements also maintain quality standards for originator and generic medicines.
Complete Report Scope:
- By Molecule
- Repaglinide
- Nateglinide
- Mitiglinide
- Other Meglitinide Analogues
- By Product Status
- Originator
- Generic
- By Product Type
- Single-Ingredient Products
- Fixed-Dose Combination Products
- By Distribution Channel
- Hospital Pharmacies
- Retail / Community Pharmacies
- Specialty / Mail-Order Pharmacies
- Online Pharmacies
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America is expected to account for 39.88% of the global meglitinides market in 2025. The United States remains the region’s primary revenue contributor, supported by generic product availability and a broad community pharmacy patient base. Six approved repaglinide manufacturers are expected to serve the U.S. market. By mid-2026, repaglinide prices are projected at USD 0.09-0.10 per tablet, reinforcing its position as a low-cost oral treatment option.The region faces mounting pressure from updated treatment guidelines and the increased adoption of GLP-1 receptor agonists and SGLT2 inhibitors. The ADA has narrowed the role of meglitinides and emphasized the reassessment of hypoglycemia risk. Canada and Mexico provide smaller but stable volumes through public drug benefit programs. Europe remains stable, supported by formulary utilization in Germany, France, and the United Kingdom, which issued a Tier 2 repaglinide supply notification in August 2025 for 500 mcg, 1 mg, and 2 mg tablets.
Asia-Pacific is forecast to be the fastest-growing region, registering a CAGR of 5.51% through 2031. Japan supports demand through established mitiglinide use, while China provides public reimbursement for all three primary molecules. India and Southeast Asia drive uptake of repaglinide-metformin combinations. The IDF Western Pacific region included 215 million adults with diabetes in 2024, while the Middle East and North Africa is projected to record 95% growth in diabetes cases by 2050. Brazil and Argentina support demand through public procurement of low-cost oral treatments.
List of Companies Covered in this Report:
- Beijing Foyou Pharma
- Elixir Pharmaceuticals
- Hansoh Pharma
- KISSEI PHARMACEUTICAL
- Novo Nordisk
- Teva Pharmaceutical Industries
- Takeda Pharmaceuticals
- Viatris
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Beijing Foyou Pharma
- Elixir Pharmaceuticals
- Hansoh Pharma
- Kissei Pharmaceuticals
- Novo Nordisk
- Teva Pharmaceuticals
- Takeda
- Viatris

